Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Bovine, Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptides corresponding to residues 345-354 of Gi 1 and 346-355 of Gi 2.|
|Contains||0.08% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||5-10 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for this product is IMR-5 cells or brain lysate.
GTP-binding proteins (G-proteins) play a critical role in signal transduction by coupling receptors to effectors. The intracellular consequences of G-protein activation include second messenger generation, protein phosphorylation, ion channel activation, gene induction, cell growth, and differentiation. Gi belongs to the pertussis toxin sensitive G-proteins. Gi consists of three different subtypes of a-subunits (ai1, ai2 and ai3)
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
adenylate cyclase-inhibiting G alpha protein; BR; CD49B; G alpha inhibitory type 2 (a); G alpha inhibitory type 2 (b); GPIa; GTP-binding protein (G-alpha-i2); GTP-binding regulatory protein Gi alpha-2 chain; guanidine nucleotide binding protein, (G protein) , alpha inhibiting activity polypeptide 2; guanine nucleotide binding protein (G protein), alpha inhibiting 2; guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2; guanine nucleotide binding protein, alpha inhibiting 2; guanine nucleotide binding protein, alpha inhibiting activity polypeptide 2; guanine nucleotide-binding protein G(i) subunit alpha-2; guanine nucleotide-binding protein G(i), alpha-2 subunit; VLA-2; VLAA2
BOS_20921; C76432; Galphai2; Gia; GIP; Gnai-2; GNAI2; GNAI2B; H_LUCA15.1; H_LUCA16.1